» Articles » PMID: 12846816

Multiple Myeloma Biology: Lessons from the 5TMM Models

Overview
Journal Immunol Rev
Date 2003 Jul 9
PMID 12846816
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a B cell neoplasm characterized by the monoclonal proliferation of plasma cells in the bone marrow, the development of osteolytic lesions and the induction of angiogenesis. These different processes require three-dimensional interactions, with both humoral and cellular contacts. The 5TMM models are suitable models to study these interactions. These murine models originate from spontaneously developed myeloma in elderly mice, which are propagated by in vivo transfer of the myeloma cells into young syngeneic mice. In this review we report on studies performed in the 5TMM models with special emphasis on the homing of the myeloma cells, the characterization of the migrating and proliferating clone and the identification of the isotype switch variants. The bone marrow microenvironment was further targeted with osteoprotegerin (OPG) to block the RANK/RANKL/OPG system and with potent bisphosphonates. Both treatments resulted in a significant protection against myeloma-associated bone disease, and they decreased myeloma disease, as evidenced by a lower tumor load and an increased survival of the mice. These different studies demonstrate the strength of these models, not only in unraveling basic biological processes but also in the testing of potentially new therapeutic targets.

Citing Articles

The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward.

Ram M, Fraser M, Vieira Dos Santos J, Tasakis R, Islam A, Abo-Donia J Pharmgenomics Pers Med. 2024; 17:573-609.

PMID: 39723112 PMC: 11669356. DOI: 10.2147/PGPM.S350238.


A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages.

Verheye E, Kancheva D, Satilmis H, Vandewalle N, Fan R, Bardet P J Hematol Oncol. 2024; 17(1):107.

PMID: 39511632 PMC: 11546219. DOI: 10.1186/s13045-024-01629-3.


IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma.

Pisano M, Sun F, Cheng Y, Parashar D, Zhou V, Jing X Haematologica. 2023; 108(12):3372-3383.

PMID: 37439384 PMC: 10690922. DOI: 10.3324/haematol.2022.282538.


An indium-111-labelled membrane-targeted peptide for cell tracking with radionuclide imaging.

Pruller J, Pham T, Blower J, Charoenphun P, Volpe A, Sunassee K RSC Chem Biol. 2023; 4(1):65-73.

PMID: 36685254 PMC: 9811519. DOI: 10.1039/d2cb00164k.


CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma.

de Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E Oncoimmunology. 2021; 10(1):2000699.

PMID: 34777918 PMC: 8583167. DOI: 10.1080/2162402X.2021.2000699.